TY  - JOUR
AU  - Bjekić-Macut, Jelica
AU  - Vukašin, Tamara
AU  - Velija-Ašimi, Zelija
AU  - Bureković, Azra
AU  - Zdravković, Marija
AU  - Andrić, Zoran
AU  - Branković, Marija
AU  - Crevar-Marinović, Slobodanka
AU  - Mandić, Tatjana
AU  - Stanojlović, Olivera
AU  - Vojnović-Milutinović, Danijela
AU  - Livadas, Sarantis
AU  - Mastorakos, George
PY  - 2021
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4307
AB  - Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.
PB  - Bentham Science Publishers
T2  - Current Pharmaceutical Design
T1  - Polycystic Ovary Syndrome: A Contemporary Clinical Approach
VL  - 27
DO  - 10.2174/1381612827666210119104721
SP  - 1
EP  - 9
ER  - 

@article{
author = "Bjekić-Macut, Jelica and Vukašin, Tamara and Velija-Ašimi, Zelija and Bureković, Azra and Zdravković, Marija and Andrić, Zoran and Branković, Marija and Crevar-Marinović, Slobodanka and Mandić, Tatjana and Stanojlović, Olivera and Vojnović-Milutinović, Danijela and Livadas, Sarantis and Mastorakos, George",
year = "2021",
abstract = "Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.",
publisher = "Bentham Science Publishers",
journal = "Current Pharmaceutical Design",
title = "Polycystic Ovary Syndrome: A Contemporary Clinical Approach",
volume = "27",
doi = "10.2174/1381612827666210119104721",
pages = "1-9"
}

Bjekić-Macut, J., Vukašin, T., Velija-Ašimi, Z., Bureković, A., Zdravković, M., Andrić, Z., Branković, M., Crevar-Marinović, S., Mandić, T., Stanojlović, O., Vojnović-Milutinović, D., Livadas, S.,& Mastorakos, G.. (2021). Polycystic Ovary Syndrome: A Contemporary Clinical Approach. in Current Pharmaceutical Design
Bentham Science Publishers., 27, 1-9.
https://doi.org/10.2174/1381612827666210119104721

Bjekić-Macut J, Vukašin T, Velija-Ašimi Z, Bureković A, Zdravković M, Andrić Z, Branković M, Crevar-Marinović S, Mandić T, Stanojlović O, Vojnović-Milutinović D, Livadas S, Mastorakos G. Polycystic Ovary Syndrome: A Contemporary Clinical Approach. in Current Pharmaceutical Design. 2021;27:1-9.
doi:10.2174/1381612827666210119104721 .

Bjekić-Macut, Jelica, Vukašin, Tamara, Velija-Ašimi, Zelija, Bureković, Azra, Zdravković, Marija, Andrić, Zoran, Branković, Marija, Crevar-Marinović, Slobodanka, Mandić, Tatjana, Stanojlović, Olivera, Vojnović-Milutinović, Danijela, Livadas, Sarantis, Mastorakos, George, "Polycystic Ovary Syndrome: A Contemporary Clinical Approach" in Current Pharmaceutical Design, 27 (2021):1-9,
https://doi.org/10.2174/1381612827666210119104721 . .

TY  - JOUR
AU  - Bjekić-Macut, Jelica
AU  - Radosavljević, Vojislav
AU  - Andrić, Zoran
AU  - Ilić, Dušan
AU  - Stanojlović, Olivera
AU  - Vojnović-Milutinović, Danijela
AU  - Božić Antić, Ivana
AU  - Zdravković, Marija
AU  - Hinić, Saša
AU  - Macut, Đuro
AU  - Žarković, Miloš
PY  - 2016
UR  - http://www.degruyter.com/view/j/jomb.2016.35.issue-4/jomb-2016-0015/jomb-2016-0015.xml
UR  - https://www.scopus.com/record/display.uri?eid=2-s2.0-84994910742&origin=SingleRecordEmailAlert&txGid=6CE299281CDB840158BFAC52EC5A2E1C.wsnAw8kcdt7IPYLO0V48gA:63#
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2522
AB  - Background: Systemic inflammatory response syndrome (SIRS) changes cortisol dynamics and indicates dissociation between the adrenal cortex and the hypothalamo-pituitary unit. The aim of this study was to assess the cortisol response after stimulation with ACTH(1-24) in patients with SIRS at admission to the Respiratory Intensive Care Unit (RICU),and seven days later.

Methods: Fifty-four subjects were included in the study, and SIRS was defined according to the Consensus Conference criteria from 1992. Severity of the disease was determined using the APACHE II score, and organ dysfunction using the SOFA score. Low-dose (1 mu g) ACTH test (LDT) was performed in all patients, and cortisol was determined along with basal ACTH. Data were analyzed using parametric and nonparametric tests and regression analysis. The results are presented as mean +/- standard deviation, and P<0.05 was considered statistically significant.

Results: There were no differences in cortisol values between the two LDTs. Cortisol increment lower than 250 nmol/L during the LDT was found in 14/54 (25.9%) subjects at the onset of SIRS. Five out of 54 (9.6%) patients died within 7 days from the onset of SIRS. Female sex and maximal cortisol response (Delta max) on LDT predicted the duration of hospitalization in RICU, while APACHE II and SOFA scores best predicted the duration of hospitalization, mortality outcome as well as overall survival outcome.

Conclusions: A difference was found in Delta max at the diagnosis of SIRS and seven days later. Delta max, and primarily the clinical scores APACHE II and SOFA predicted the outcomes of hospitalization and overall survival.
T2  - Journal of Medical Biochemistry
T1  - Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome
IS  - 4
VL  - 35
DO  - 10.1515/jomb-2016-0015
SP  - 428
EP  - 435
ER  - 

@article{
author = "Bjekić-Macut, Jelica and Radosavljević, Vojislav and Andrić, Zoran and Ilić, Dušan and Stanojlović, Olivera and Vojnović-Milutinović, Danijela and Božić Antić, Ivana and Zdravković, Marija and Hinić, Saša and Macut, Đuro and Žarković, Miloš",
year = "2016",
abstract = "Background: Systemic inflammatory response syndrome (SIRS) changes cortisol dynamics and indicates dissociation between the adrenal cortex and the hypothalamo-pituitary unit. The aim of this study was to assess the cortisol response after stimulation with ACTH(1-24) in patients with SIRS at admission to the Respiratory Intensive Care Unit (RICU),and seven days later.

Methods: Fifty-four subjects were included in the study, and SIRS was defined according to the Consensus Conference criteria from 1992. Severity of the disease was determined using the APACHE II score, and organ dysfunction using the SOFA score. Low-dose (1 mu g) ACTH test (LDT) was performed in all patients, and cortisol was determined along with basal ACTH. Data were analyzed using parametric and nonparametric tests and regression analysis. The results are presented as mean +/- standard deviation, and P<0.05 was considered statistically significant.

Results: There were no differences in cortisol values between the two LDTs. Cortisol increment lower than 250 nmol/L during the LDT was found in 14/54 (25.9%) subjects at the onset of SIRS. Five out of 54 (9.6%) patients died within 7 days from the onset of SIRS. Female sex and maximal cortisol response (Delta max) on LDT predicted the duration of hospitalization in RICU, while APACHE II and SOFA scores best predicted the duration of hospitalization, mortality outcome as well as overall survival outcome.

Conclusions: A difference was found in Delta max at the diagnosis of SIRS and seven days later. Delta max, and primarily the clinical scores APACHE II and SOFA predicted the outcomes of hospitalization and overall survival.",
journal = "Journal of Medical Biochemistry",
title = "Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome",
number = "4",
volume = "35",
doi = "10.1515/jomb-2016-0015",
pages = "428-435"
}

Bjekić-Macut, J., Radosavljević, V., Andrić, Z., Ilić, D., Stanojlović, O., Vojnović-Milutinović, D., Božić Antić, I., Zdravković, M., Hinić, S., Macut, Đ.,& Žarković, M.. (2016). Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome. in Journal of Medical Biochemistry, 35(4), 428-435.
https://doi.org/10.1515/jomb-2016-0015

Bjekić-Macut J, Radosavljević V, Andrić Z, Ilić D, Stanojlović O, Vojnović-Milutinović D, Božić Antić I, Zdravković M, Hinić S, Macut Đ, Žarković M. Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome. in Journal of Medical Biochemistry. 2016;35(4):428-435.
doi:10.1515/jomb-2016-0015 .

Bjekić-Macut, Jelica, Radosavljević, Vojislav, Andrić, Zoran, Ilić, Dušan, Stanojlović, Olivera, Vojnović-Milutinović, Danijela, Božić Antić, Ivana, Zdravković, Marija, Hinić, Saša, Macut, Đuro, Žarković, Miloš, "Cortisol Response to Low-Dose (1 μg) ACTH Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome" in Journal of Medical Biochemistry, 35, no. 4 (2016):428-435,
https://doi.org/10.1515/jomb-2016-0015 . .